ClinVar Miner

Submissions for variant NM_000527.5(LDLR):c.188G>A (p.Cys63Tyr)

dbSNP: rs879254427
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
LDLR-LOVD, British Heart Foundation RCV000237751 SCV000294499 likely pathogenic Hypercholesterolemia, familial, 1 2016-03-25 criteria provided, single submitter literature only
Fundacion Hipercolesterolemia Familiar RCV000237751 SCV000607425 uncertain significance Hypercholesterolemia, familial, 1 2016-03-01 criteria provided, single submitter research
Ambry Genetics RCV002411078 SCV002719413 likely pathogenic Cardiovascular phenotype 2021-12-17 criteria provided, single submitter clinical testing The p.C63Y variant (also known as c.188G>A and legacy p.C42Y), located in coding exon 2 of the LDLR gene, results from a G to A substitution at nucleotide position 188. The cysteine at codon 63 is replaced by tyrosine, an amino acid with highly dissimilar properties. Pathogenic LDLR mutations that result in the substitution or generation of cysteine residues within the cysteine-rich LDLR class A repeats and EGF-like domains are common in familial hypercholesterolemia (FH) (Villéger L. Hum Mutat. 2002;20(2):81-7). This particular cysteine alteration has been reported in individuals with hypercholesterolemia (Ambry internal data; Alonso R et al. Clin Biochem, 2009 Jun;42:899-903; Leren TP et al. Atherosclerosis, 2021 04;322:61-66). Two other alterations at the same codon, p.C63R (c.187T>C) and p.C63F (c.188G>T), have also been detected in individuals with hypercholesterolemia (Wang J et al. Hum Mutat, 2001 Oct;18:359; Lombardi MP et al. Genet Test, 2006;10:77-84; Rieck L et al. Clin Genet, 2020 11;98:457-467). Internal structural analysis indicates this alteration eliminates a disulfide bond critical for the structural integrity of the LDLR class A repeat 1 (Ambry internal data). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.